unknown
Stage
About
Innervate Radiopharmaceuticals develops PET imaging and therapeutic radiopharmaceuticals, with a lead asset 18F-metafluorobenzylguanidine (mFBG) aimed at improving detection and management of neuroblastoma. The company is conducting a pivotal Phase III clinical trial in neuroblastoma patients and a Phase I/IIa study evaluating mFBG for myocardial sympathetic innervation.
Explore Innervate Radiopharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.